Conference Schedule

The ASPHO Vascular Anomalies SIG presents an educational primer for providers and trainees on clinical, radiographic, and molecular updates in pediatric vascular anomalies. The primer will cover board review material and go further to equip pediatric hematologists/oncologists with knowledge on how to recognize common vascular anomalies based on their clinical features and presentation, as well as the availability of advanced diagnostic techniques and multi-modality treatment approaches including medical therapies.

Learning Objectives:

• Review current approaches to diagnosis and management of vascular anomalies, discuss the differential diagnosis using a multi-disciplinary and multi-modal treatment approach
• Review conventional and advanced imaging modalities, review interventional radiology techniques utilized for the treatment of vascular anomalies
• Review current understanding of molecular pathways and molecular testing in the pathophysiology and diagnosis of vascular anomalies

Moderator: 

• Classifying Vascular Anomalies
  • Taizo Nakano, MD

Speakers:

• Dynamic Vascular Tumors
  • Sally J. Cohen-Cutler, MD MS
• Dynamic Vascular Malformations
  • Kiersten Ricci, MD
• Advances in Molecular Diagnostics
  • Jimmy Bennet, MD
• Targeted Pharmacotherapy for Vascular Anomalies
  • Whitney Eng, MD MPH
• Comprehensive Care and Quality of Life
  • Bryan Sisk, MD MS
• IR/Surgical/Derm
  • Matthew Hawkins, MD 
• Coagulopathies of Vascular Anomalies
  • Joana Mack, MD

The Vascular Anomalies SIG will meet at the conclusion of the Pre-Conference Primer.

Welcome
President, Caroline Hastings, MD, welcomes all attendees to the 2024 ASPHO Conference.

Plenary Papers
The Plenary Papers were selected by the 2024 Conference Planning Committee as the most highly rated abstract submissions.

Moderators: Karen E. Effinger, MD MS; Jessica Heath, MD

Zaina Inam
IMPACT OF PRE-HSCT RBC ALLOIMMUNIZATION ON POST-HSCT OUTCOMES IN PEDIATRIC PATIENTS WITH SCD (Plenary Paper)

C. Michel Zwaan
PIVOTAL PHASE 2 RESULTS OF AUGMENT-101 FOR REVUMENIB IN KMT2Ar ACUTE LEUKEMIA: PEDIATRIC EXPERIENCE (Plenary Paper)

Young Investigator Award Presentations
The ASPHO Young Investigator Award was established to formally recognize excellence in research in pediatric hematology/oncology and to promote basic and clinical investigation into the fields of hematology/oncology by fellows and faculty members who are less than 4 years post-fellowship.

Moderators: Karen E. Effinger, MD MS; Jessica Heath, MD

Lindsay Schwartz, MD MS - University of Chicago
LONGITUDINAL OVARIAN RESERVE IN ADOLESCENTS WITH LYMPHOMA: CHILDREN’S ONCOLOGY GROUP STUDY ALTE 11C1

Rachel Offenbacher, MD
TARGETING THE UREA CYCLE TO PREVENT AND TREAT METASTATIC OSTEOSARCOMA

Early Career Travel Stipend Award Announcements

• Franklin Chien, MD MS - Emory University School of Medicine/Children's Healthcare of Atlanta
  CIRCULATING TUMOR CELLS IN MEDULLOBLASTOMA: A POTENTIAL NOVEL PERIPHERAL BIOMARKERS FOR CNS DISEASE
  Presenting an oral abstract on Friday, April 5 at 8 am during the "Oncology Paper Session with Luminary Investigator".
  
  
• Dipti Kamath, MD - UCSF Benioff Children's Hospital
  MICROFLUIDIC INSIGHT INTO GENE-EDITED RBCs FOR SICKLE CELL DISEASE
  Presenting a poster on Thursday evening in the Exhibit Hall - poster #103
  
  
• Julie Ma, MD - Children's Hospital Los Angeles
  TARGETING MICROENVIRONMENT PATHWAYS TO IMPROVE CAR-T CELL EFFICACY IN B-ALL
  Presenting an oral abstract on Friday at 8 am during the "Oncology Paper Session with Luminary Investigator".
  
  
• Jaime Josue Baldeon Mendoza, MD FAAP - Cleveland Clinic Children's
  THE UNCONVENTIONAL MYOSIN FAMILY PROTEIN MYO18A IS A NOVEL REGULATOR OF B CELL DEVELOPMENT
  Presenting a poster on Friday in the Exhibit Hall - poster #702
  
  
• Katelyn Purvis, MD - St. Jude Children's Research Hospital
  OUTCOMES IN PATIENTS WITH ETV6: RUNX1 OR HYPERDIPLOID B-ALL IN THE ST. JUDE TOTAL 15 AND 16 STUDIES
  Presenting a poster on Friday in the Exhibit Hall - poster #710

Advanced Practice Provider Travel Stipend Award Annoucement

• Bonnie Yates, MS CPNP-AC - National Institutes of Health (NIH)
  CD22 CART FOR CHILDREN AND YOUNG ADULTS WITH R/R B-CELL ALL: RESULTS FROM A 10-YEAR-EXPERIENCE
  Presenting an oral abstract on Friday at 8 am during the "Oncology Paper Session with Luminary Investigator".

Join fellow Division Directors for a deep dive into relevant and timely topics, gain new insights to address challenges in your role, and enjoy engaging with colleagues during this newly designed event. A social hour will follow the event and is included in the fee.

Advanced registration and fee are required.

Moderators:

• Rishi Lulla, MD MS 
• Linda McAllister-Lucas, MD PhD

Speakers:

• Recruitment and Retention
  • Valerie Opipari, MD (University of Michigan Medical School; Mott Children’s Hospital)
• Mentorship Workshop
  • Giana H Davidson, MD, MPH, FACS (University of Washington School of Medicine)

Mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia, accounting for 2-5% of all cases, with blasts having both lymphoid and myeloid features. Advancements in understanding MPAL biology and tailoring specific therapy for this rare leukemia have remained challenging due to: (a) the changing and relatively subjective diagnostic criteria for MPAL, (b) the wide phenotypic and genomic diversity among MPAL cases and (c) the historical exclusion of MPAL cases from clinical trials. Here, we will learn about the updated diagnostic criteria, review the latest biological findings, and discuss the current treatment strategies for this rare disease.

Learning Objectives:

• Review the changes in diagnostic criteria for MPAL over the past several decades and learn about the most updated classification system described by the World Health Organization (WHO) and International Consensus Classification (ICC)
• Describe our current understanding of the biology of MPAL by reviewing the most updated MPAL literature in terms of genetics, transcriptomics, and single cell analysis
• Discuss the current treatment strategies used to treat pediatric MPAL and examine potential new strategies to treat this rare malignancy

Speakers:

• Defining the genomic and molecular landscape of pediatric MPAL
  
  • Sunil S. Raikar, MD
    
• Flow cytometric analysis of MPAL: Update of the WHO and ICC diagnostic criteria
  
  • Alexandra Kovach, MD
    
• Current updates in treatment strategies for pediatric MPAL
  
  • Thomas Alexander, MD MPH

Experts will discuss the psychosocial challenges faced by pediatric patients and their families, highlighting evidence-based interventions and support programs aimed at promoting emotional well-being, coping strategies, and resilience for pediatric patients and their families during treatment and survivorship. They will explore the neurocognitive impact of CNS impacting disease and treatments and describe emerging empirical support for interventions designed to mitigate (or even prevent) neurocognitive late effects. They will focus on the unique psychosocial needs of AYA patients and survivors and discuss tailored support programs to improve functioning and quality of life during and after treatment.

Learning Objectives:

• Understand the psychosocial challenges faced by pediatric patients and their families, and explore evidence-based interventions to enhance emotional well-being and resilience during treatment and survivorship
• Gain insights into the neurocognitive impact of CNS impacting disease and treatments and evidence-based interventions that support cognitive functioning in this patient population
• Recognize and address unique psychosocial needs of Adolescent and Young Adult (AYA) cancer patients and explore tailored interventions to enhance their overall quality of life during and after cancer treatment

Moderator:

• Adam Esbenshade, MD MSCI

Speakers:

• Dina Hankin, PhD
• Leanne Embry, PhD
• Heather Conklin, PhD

About 10% of high school students identify as gender non-congruent, and many of those are transgender leading to an increased use of medications with potentially serious hematologic adverse effects (thrombosis, erythrocytosis, etc.) Hematologists are being asked to provide consultation to the transgender community regarding critical management questions. In addition, new nomenclature regarding the diagnosis of hemophilia carriers which is gender neutral has been published. Moreover, there are clinics for adolescents which often use gender-specific terms (e.g., Young Women’s Clinic) whose names should be reconsidered. It is imperative that using appropriate terms/names for diagnoses/clinics be appreciated by all pediatric hematologists.

Learning Objectives:

• Gain knowledge on the basics of transgender medicine including appropriate terminology and the medical aspects of therapy
• Describe the hematologic manifestations of medications utilized in transgender medicine and how to mitigate the risks of such treatments
• Learn the new gender-neutral hemophilia nomenclature and to discuss the proper terminology for specialty clinics caring for adolescents

Moderator: 

• Guy Young, MD

Speakers:

• Ximena Lopez, MD
• Angela C. Weyand, MD
• Robert Sidonio, Jr., MD MSc

Epstein-Barr virus (EBV) associated lymphoproliferation and hyperinflammation occur in various contexts, often presenting unique challenges to Hematology oncology and BMT physicians. This joint session aims to delve into the complexities of EBV-driven lymphoma, post-transplant lymphoproliferative disorder (PTLD), and hemophagocytic lymphohistiocytosis (HLH) in relation to inborn errors of immuinty (IEI) allogeneic bone marrow transplantation (BMT), solid organ transplants, and systemic EBV-positive T-cell lymphomas of childhood. By dissecting the connections between EBV, PTLD, HLH, and IEI, this session seeks to unmask the spectrum of EBV-associated lymphoproliferation and hyperinflammation complications. Many of these complications need active collaboration between Hematology, oncology, BMT, and immunology. We aim to stimulate discussion and collaboration among clinicians, researchers, and other stakeholders through a multidisciplinary approach to address the challenges and opportunities in managing these complex and often life-threatening conditions.

Learning Objectives:

• Discuss the challenges in identifying these rare IEI presenting with EBV, lymphoma and the implications for treatment and management
• Examine the prevalence and risk factors and treatment of PTLD following both stem cell and solid transplantation
• Investigate the complex manifestations of EBV-driven hyperinflammation and lymphoproliferation, particularly when EBV infects T and NK cells

Moderator: 

• Hemalatha G. Rangarajan, MD

Speakers:

• EBV-driven lymphoma as a presenting manifestation of underlying primary immune deficiency
  • Shanmuganathan Chandrakasan, MD
• EBV-associated HLH, chronic active EBV infection (CAEBV), and systemic EBV-positive T-cell lymphoma
  • Nader El-Mallawany, MD
• EBV Lymphoproliferative Disease in Allogeneic Hematopoietic Stem Cell and Solid Organ Transplant
  
  • Susan Prockop, MD

This session will review the paradigm-changing advances in mechanistic insights of LCH over the past decade. We will discuss the current front-line standard of care chemotherapy, rooted in the pre-molecular era, with reliably suboptimal outcomes. With updated conceptual framework of LCH being caused by activating MAPK pathway somatic mutations in myeloid precursor cells, we will explore opportunities to improve outcomes for patients with refined approaches to diagnosis, front-line therapy, salvage therapy and treatment for LCH-associated neurodegeneration. We will review clinical trials underway, and finally, will discuss management strategies while we await results from clinical trials testing transformational therapeutic strategies.

Learning Objectives:

• Understand mechanistic frameworks for LCH pathogenesis
• Review rationale for current diagnostic and therapeutic approaches
• Discuss opportunities to optimize improvement in outcomes through clinical trials

Moderator: 

• Nitya Gulati

Speakers:

• LCH: History, modern mechanistic insights and therapeutic opportunities
  • Carl Allen, MD PhD
• Is this LCH?
  • Jennifer Picarsic, MD
• Stun or Kill? Clinical challenges and opportunities to improve lives of patients with LCH
  • Michelle Hermiston, MD PhD

Sickle Cell disease was once considered a disease of childhood. Through advances in clinical care pediatric hematology practitioners can expect their patients to live well into adulthood. It has been described that academic achievement of children with sickle cell disease is below that of their peers. The focus for practitioners must now shift from mere survival and prevention of serious physical complications to optimization of educational and occupational opportunities in childhood and adulthood. In order to achieve these goals, patients must have access to neurocognitive assessment and neuropsychiatric services as appropriate. Published guidelines recommend neurocognitive screening for patients with sickle cell disease however this practice is not universal. Beyond that, practitioners must know when to seek out neuropsychiatric services for their patients as access to such services can be a challenge. Pediatric hematology providers need to learn the most recent evidence, available tools, and best practices to optimize neurocognitive outcomes for their patients.

Learning Objectives:

• Describe the role of cognitive assessment in sickle cell disease and list barriers and facilitators to implementation of cognitive assessment
• Discuss what is known and unknown about the role hydroxyurea may play in improving cognition in patients with sickle cell disease
• Describe how neurocognitive testing and interventions can be beneficial to adolescents with sickle cell disease as they transition to adult care.

Moderator: 

• Alex George, MD PhD
• Patrick McGann, MD MS

Speakers:

• Neurocognitive Assessment in Sickle Cell Disease
  • Andrew Heitzer, PhD ABPP-CN
    
• Optimizing Neurocognition Through Medical Therapy
  • Kristine Karkoska, MD
• Neurocognition and Transition
  • Allison King, MD MPH PhD

Join fellow new members, first-time attendees, and international attendees during this opportunity to connect and network. Learn about the Society’s special interest groups at the SIG Meet & Greet which will take place at the reception.

• Advanced Practice Provider
• Hospitalist Medicine
• Well-Being

Join this session and interact with a recognized expert on a challenging diagnostic and management issue. The session is scheduled for 1 hour and will include a 15-20 minute presentation by Dr. Joanna Weinstein on the general approach to treatment of cancer in patients with a cancer predisposition syndrome followed by small group discussion of additional cases shared by the attendees.

Come prepared to ask questions and share your cases.

Advanced registration and fee are required. Seating is limited to 30. The registration fee is $25.

Join this session and interact with a recognized expert on a challenging diagnostic and management issue. The session is scheduled for 1 hour and will include a 15-20 minute presentation by Dr. Melissa Rose on the general approach to severe aplastic anemia followed by small group discussion of additional cases shared by the attendees.

Come prepared to ask questions and share your cases.

Advanced registration is required. Seating is limited to 30. The registration fee is $25.

Dr. Will Flanary is an ophthalmologist and comedian who moonlights in his free time as “Dr. Glaucomflecken,” a social media personality who creates medical-themed comedy shorts to an audience of over 4 million across social media. His humor has been shaped by the challenges of medical training and by his experiences as a patient.

Dr. Flanary is a 2-time testicular cancer survivor as well as a survivor of cardiac arrest, saved by his intrepid wife and her timely CPR. Initially used as a creative outlet to cope with these health challenges, Dr. Flanary’s comedy has evolved over time to incorporate biting satire of the US health care system, academic publishing, and interpersonal conflicts pervasive in the medical system. He is a frequent keynote speaker who encourages medical audiences to embrace humor in everyday life.

There are a number of true emergencies in sickle cell disease which require the on-call hematologist to quickly recognize that a situation has the potential to become rapidly fatal. With expedited management and mobilization of additional resources, patients can be appropriately treated. It has been well described that acute fat embolism syndrome, delayed hemolytic transfusion reaction, and acute pulmonary embolism are life threating complications for patients with sickle cell disease. These conditions can be mistaken for the more common an acute painful crisis and acute chest syndrome. Thus, these life-threatening complications are under-recognized and under-reported putting patients at risk for increased morbidity and mortality. It is critical that pediatric hematology providers are aware of these conditions in pediatric patients and are ready to act fast.

Learning Objectives:

• Discuss three emergencies in sickle cell disease in which providers must act intervene quickly to prevent morbidity and mortality
• List clinical features, diagnostic tools, and management strategies for the 3 emergencies in sickle cell disease covered in this session

Moderator: 

• Caitlin Neri, MD

Speakers:

• Acute Fat embolism Syndrome
  • Radhika Gangaraju, MD MSPH
• Delayed Hemolytic Transfusion Reaction
  • Satheesh Chonat, MD
• Acute Pulmonary Embolism in Sickle Cell Disease
  • Clay Cohen, MD

Brain tumors are the leading cause of cancer deaths in children, and relapsed patients are rarely able to achieve a cure. Cellular immunotherapy regimens, including CAR T cell therapies, have emerged as promising new treatment options and have begun early-phase clinical trials in children. These novel treatments vary in their molecular targets, design of gene therapy constructs or manner of ex vivo leukocytes stimulation, lympholytic preparative regimens, timing of interventions, etc. This session will provide the audience with updates and interim results for active clinical studies, followed by an interactive panel discussion.

Learning Objectives:

• Update knowledge regarding availability, safety, and potential benefit of cellular immunotherapy clinical trials for patients with childhood CNS tumors
• Engage experts in the cellular immunotherapy field in a discussion of the finer points of designing such therapies and the clinical trials that provide access to them

Moderator: 

• Theodore S. Johnson, MD PhD

Speakers:

• HER2 CAR T cells (NCT02442297, NCT04903080)
  • Shoba A. Navai, MD
• IL13Rα2 CAR T cells (NCT04510051)
  • Leo Wang, MD PhD
• From single to multi-antigen targeting CAR T cell trials (NCT04185038, NCT03500991, NCT05768880)
  • Nicholas A. Vitanza, MD
• Autologous tumor antigen associated T cells (NCT03652545)
  • Eugene Hwang, MD

Over 25 million individuals in the US speak languages other than English (LOE). Despite federal regulations mandating meaningful access for healthcare, patients who speak LOE receive unequal access to clinical care and research, consequently experiencing lower patient satisfaction, lower medication adherence, lower research participation, and greater preventable morbidity and mortality. These disparities are particularly impactful in pediatric hematology/oncology, where complex diagnoses and treatment regimens, and lengthy clinical trial consents are commonplace. This session will provide background about language disparities in research and clinical practice and provide practical strategies for improving language equity in pediatric hematology/oncology.

Learning Objectives:

• Describe how language access impacts patient safety, quality, and equity
• Identify strategies to promote language equity during informed consent for pediatric hematology/oncology research
• Discuss practical strategies to improve clinical care and increase research participation for families who speak languages other than English in pediatric hematology/oncology and stem cell transplantation

Moderator:

• Jenny Ruiz, MD MSCE

Speakers:

• Language Equity and Patient Safety in Pediatrics
  • Alisa Khan, MD
• “COMPRENDO”: A culturally and linguistically- appropriate intervention to improve informed consent
  • Paula Aristizabal, MD MS
• Practical Strategies to Improve Clinical Care
  • Joanna Robles, MD
• Practical Strategies to Increase Research Participation
  • Luisanna M. Sanchez, MD

ASPHO’s annual business meeting allows attendees to learn more about the Society’s progress toward meeting the goals of its strategic plan, efforts in advocating for its members and our patients, and the Society’s financial health. Additionally, outgoing Board members and committee chairs are recognized and a report is presented from the Pediatric Blood & Cancer Journal editor.

• Hemoglobinopathies
• Physician Scientist
• Quality Improvement and Patient Safety
• Small Program

This session provides early-career professionals (new attendings, trainees and medical students/residents) a forum to discuss specific issues with leaders in the field, ask questions related to career development, and receive positive reinforcement regarding career goals specific to their interests, all in a small group setting.

Advanced registration is required.

The annual George R. Buchanan Lectureship is presented in honor of Dr. Buchanan and his many contributions to ASPHO and the field of pediatric hematology/oncology. It is awarded to an internationally recognized expert in pediatric hematology/oncology. This year's lectureship will be presented by Prakash Satwani, MBBS MD from Columbia University Medical Center and NewYork-Presbyterian Hospital.

Although an association between inherited bone marrow failure syndromes (IBMFS) and cancer predisposition has been well established, emerging data from registry and collaborative research studies have shown an unexpectedly high incidence of previously unrecognized cancer types along with unique and disease-specific mechanisms of transformation in commonly recognized malignancies. These findings have significant implications on surveillance methods and schedules, while also providing potential strategies for therapeutic intervention prior to transformation or targeted treatment of established cancers. In this session, we will review new findings regarding the incidence and distinctive mechanisms of myeloid malignancies, solid tumors, and myelodysplastic syndromes in pediatric IBMFS.

Learning Objectives:

• Describe the risk, spectrum, and biology of hematologic and solid tumor neoplasms in IBMFS
• Identify the rationale and modalities for cancer screening in IBMFS populations including both traditional and molecularly based methods
• Recognize that pediatric-onset myelodysplastic syndrome may be the presenting feature of an underlying BMF disorder
• Understand the role for registry-based and collaborative research efforts to develop evidence-based guidelines for cancer screening in IBMFS

Speakers:

• Moderator and Introduction to Pediatric MDS and Novel IBMFS
  • Jason Farrar, MD
• Leukemia Surveillance in Shwachman Diamond Syndrome
  • Akiko Shimamura, MD PhD
• Non-Hematologic Cancers in Diamond Blackfan Anemia and Fanconi Anemia
  • Adrianna Vlachos, MD
• Pediatric MDS: SAMD9/9L syndromes and Beyond
  • Marcin Wlodarski, MD PhD
• Transplant for hematologic malignancy in IBMFs
  • Jane Koo, MD

Emerging artificial intelligence (AI) technologies, including machine learning and large language models (e.g., ChatGPT) are widely applied outside of healthcare. Applications in medicine–including pediatric hematology/oncology–have lagged, in part due to reliance on unstructured data, limited interoperability of technology systems and privacy regulations. While AI has potential benefits for pediatric hematology/oncology, it also poses potential pitfalls. In this interactive workshop, AI technologies will be demystified and explained at a conceptual level. Attendees will understand strengths and limitations of various AI technologies and explore how they can be applied to problems in pediatric hematology/oncology.

Learning Objectives:

• Understand basics of artificial intelligence, machine learning and large language models, such as ChatGPT
• Identify strengths and limitations of various artificial intelligence technologies
• Explore use of artificial intelligence to solve contemporary problems in pediatric hematology/oncology and in medicine

Moderator: 

• Kirk Wyatt, MD MAS

Speakers:

• Wayne H. Liang, MD MS
• Gerard Hills, MD

Treatment for high-risk (HR) neuroblastoma has changed throughout the years with huge strides made in improving survival through the last several decades. The FDA approval of GD2-targeted antibodies, dinutuximab and naxitamab, has paved the way for more precise treatments, but we continue to work to understand their full value. In a subset of HR neuroblastoma patients with ALK alterations, novel inhibitors such lorlatinib are changing treatment as we still work to understand their biology and the potential to develop resistance. With all these additional therapies, it has become exceedingly important to also study the long-term health impact on survivors.

Learning Objectives:

• Review GD2-related antibody therapies and use of these antibodies in upfront therapy for patients with high-risk neuroblastoma
• Review the role of ALK inhibitors in neuroblastoma and the utility of liquid biopsy for monitoring of resistance
• Discuss the late effects encountered in survivors of HR neuroblastoma therapy

Moderators: 

• Michael Ferguson, MD MS 
• Colin Moore, MD 

Speakers:

• Sara Federico, MD
• Kelly Goldsmith, MD
• Eric J. Chow, MD MPH

Join fellow Fellowship Program Directors for an opportunity to network and connect around topics important to your role.

Advanced registration is required.

Luminary Speaker: Maryam Fouladi, MD

Paper Presenters:

• Frank Chien, MD
  CIRCULATING TUMOR CELLS IN MEDULLOBLASTOMA: A POTENTIAL NOVEL PERIPHERAL BIOMARKERS FOR CNS DISEASE (Early Career Travel Stipend Award Recipient)
  
  
• Jay Shah, MBBS MD
  TARGETING C-MET: IMPROVING EFFICACY OF CAR T-CELLS FOR TREATMENT OF AGGRESSIVE SOLID & BRAIN TUMORS
  
  
• Julie Ma, MD
  TARGETING MICROENVIRONMENT PATHWAYS TO IMPROVE CAR-T CELL EFFICACY IN B-ALL (Early Career Travel Stipend Award Recipient)
  
  
• Bonnie Yates, MS CPNP-AC
  CD22 CART FOR CHILDREN AND YOUNG ADULTS WITH R/R B-CELL ALL: RESULTS FROM A 10-YEAR-EXPERIENCE

Luminary Speaker: Jorge A. Di Paola, MD

Paper Presenters:

• Sally Azer, MD
  EVALUATING THE BIOPHYSICS OF PLATELET ADHESION AND GEOMETRY-SENSING IN MILD BLEEDING DISORDERS
  
  
• Annegret Holm, MD
  TARGETING A NOVEL SOX18-MEVALONATE PATHWAY AXIS TO TREAT INFANTILE HEMANGIOMA
  
  
• Mithra Lakshmi Narasimhan, MD
  OUTCOMES OF HSCT USING REDUCED INTENSITY CONDITIONING IN PEDIATRIC SEVERE APLASTIC ANEMIA
  
  
• Rachael Grace, MD MMSc
  THE CHARACTERISTICS OF PEDIATRIC PATIENTS WITH PYRUVATE KINASE DEFICIENCY AND IRON OVERLOAD